Beyond Slowing Disease: A New Gene Therapy Blueprint to Combat AMD Blindness

PARIS, France – September 16, 2026 – In the relentless battle against age-related vision loss, the current strategy has largely been one of managed decline—slowing the inevitable march of blindness. But a French biotech firm is poised to present data that could shift the paradigm from defense to offense. PulseSight Therapeutics has announced it will unveil striking results from its Phase 1 trial for PST-611, a novel gene therapy for the advanced, untreatable form of dry Age-related Macular Degeneration (AMD) known as Geographic Atrophy (GA). The data, scheduled for presentation at the prestigious EURETINA Congress in Vienna, suggests a future where we might not just slow the disease, but target its fundamental biological engine.

In a small first-in-human study, the treatment demonstrated an excellent safety profile. More remarkably, it generated early but pronounced signals of efficacy in five of the six patients treated, including spontaneous, patient-reported improvements in vision. For the millions living in the expanding grey blur of GA, this news represents a significant beacon of hope, suggesting a new frontier in ocular medicine is not just possible, but within reach.

The Unmet Crisis of Geographic Atrophy

To grasp the significance of PulseSight’s announcement, one must first understand the devastating void PST-611 aims to fill. Age-related Macular Degeneration is the leading cause of central vision loss in the elderly, affecting a staggering 200 million people worldwide. While the “wet” form of AMD has seen treatment advances, the “dry” form, which can progress to Geographic Atrophy, has remained a formidable challenge. GA is a slow, irreversible erosion of the retina, creating blind spots that gradually merge until a person can no longer read, recognize the faces of loved ones, or navigate their world independently. It affects over five million people globally, with no approved treatments available in Europe.

In the United States, two therapies—Syfovre and Izervay—have recently been approved. While celebrated as first-in-class, they offer a marginal victory. Both drugs target the complement system, a component of the immune response implicated in the inflammatory damage of GA. They can slow the growth of atrophic lesions but do not stop the disease, nor do they restore any lost vision. They represent a way to slow the descent, not halt or reverse it. This leaves a vast and urgent unmet need for therapies that can offer more profound and lasting benefits. As one retinal specialist noted, “Slowing progression is a crucial first step, but the holy grail is a treatment that can protect retinal cells and preserve, or even improve, function. That requires tackling the disease from a different angle.”

A Radical Approach: Correcting Iron Overload

PST-611 represents that different angle. Instead of targeting the downstream inflammatory effects, PulseSight’s therapy goes upstream to address a core pathological driver: iron dysregulation. Decades of research have shown that in dry AMD, the delicate balance of iron in the retina is disrupted. While essential for cellular function, an excess of free iron is highly toxic, unleashing a cascade of oxidative stress, inflammation, and a specific form of programmed cell death known as ferroptosis. This iron-induced cell death is a key culprit in the destruction of the photoreceptors and retinal pigment epithelium (RPE) cells that define GA.

PulseSight’s solution is elegantly simple in concept. Their gene therapy, PST-611, delivers a DNA plasmid that encodes for human transferrin, the body's primary protein for managing and transporting iron. By turning retinal-adjacent cells into biofactories that produce this crucial protein, the therapy aims to restore iron homeostasis. It effectively provides the tools for the eye to clean up the toxic iron excess, thereby preventing the entire destructive cascade from starting. This mechanism is not just a treatment for a symptom; it’s a direct intervention in the underlying disease biology. Preclinical studies had already demonstrated that this approach could protect retinal cells and preserve visual function in animal models, setting the stage for the promising human trial.

The Power of a Non-Viral Platform

Equally as innovative as the therapeutic target is the delivery method. Traditional gene therapies often rely on modified viruses (like adeno-associated viruses, or AAVs) to deliver their genetic payload. While effective, viral vectors can sometimes trigger immune responses, limiting their use and potential for re-dosing. PulseSight has pioneered a non-viral approach that sidesteps these issues. Their platform uses a minimally invasive procedure called electro-transfection to deliver the DNA plasmid directly into the ciliary muscle, a ring of tissue behind the iris.

This technique uses a brief electrical pulse to create temporary pores in the muscle cells, allowing the DNA to enter. Once inside, these cells become stable, long-term “biofactories,” continuously producing and secreting the therapeutic transferrin protein, which then travels to the back of the eye to protect the retina. The Phase 1 results powerfully validate this platform's design. The treatment was deemed to have “excellent safety and tolerability,” with no cases of intraocular inflammation—a key concern with some viral-vector-based therapies. This safety profile is critical for a chronic disease like GA, as it opens the door for repeated administrations, potentially every four to six months, to maintain therapeutic effect over a patient's lifetime.

Decoding the Promising Early Signals

While Phase 1 trials are primarily designed to establish safety, the early efficacy signals reported by PulseSight are too significant to ignore. The study, which followed six patients at two dose levels, found compelling evidence of a therapeutic effect in five of them. This was observed both anatomically and functionally. Anatomical data, which will be detailed further at the EURETINA congress, showed a reduction in the growth rate of the GA lesions. Data from a 12-month follow-up has indicated an average reduction in lesion growth of 47% compared to the pre-treatment rate.

Even more compelling, however, were the functional reports. Patients spontaneously reported improvements in their vision during daily activities. For a disease defined by irreversible loss, any report of functional gain is extraordinary. “It’s one thing to see a change on a retinal scan, but it’s another thing entirely for a patient to tell you they can see better,” commented a gene therapy analyst. “While we must be cautious with such a small sample size, these patient-reported outcomes are a powerful indicator that the therapy is having a meaningful impact.”

As the ophthalmology world turns its attention to Vienna for the full presentation by Dr. Georges Weissgerber, the implications are clear. PulseSight Therapeutics is not just adding another drug to the pipeline; it is validating a new platform and a new biological target. The company plans to advance PST-611 into a larger Phase 2a trial to study multiple administrations in more patients later this year. The road from a six-patient study to a global standard of care remains long and fraught with challenges, but these results provide the most crucial element for any medical revolution: a clear and compelling vision of a better future.